Incidence of Acute Renal Failure Associated With Iodinated Contrast Agents in Pediatrics
- Conditions
- Acute Renal Insufficiency
- Interventions
- Other: CT scan with iodinated contrast agents
- Registration Number
- NCT02955979
- Brief Summary
Iodinated contrast media are now frequently used in diagnostic imaging exams, including pediatrics.
In adults, the acute renal failure (ARF) associated with contrast agents (CA-AKI) occur in 3-33% of exposed patients, especially as the patient is fragile, has comorbidities or pre-existing renal aggression .
In children, the prevalence of this little known disease is probably underestimated.
The investigators intend to conduct a prospective epidemiological study, to estimate the impact of the acute renale failure to iodinated contrast agents in pediatrics.
- Detailed Description
Patients will be included those of pediatric emergencies, Hospitalization Unit of Short Duration pediatric, pediatric intensive care and pediatric resuscitation. The acute renale failure will be estimated on the basis of criteria KDIGO (score of kidney disease) group in 2012 to 48 hours a computed tomography (CT) scan with injection of contrast media, based on a change in creatinine clearance of the estimated according to the formula Schwartz revised in 2009 and / or diuresis.
Patient characteristics will be identified in order to establish risk factors.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 4
- Patients under 16 years admitted to a participating service
- Patient receiving an injected CT scan
- Prior Inclusion in the study during an earlier review.
- Opposition of parents.
- Chronic renal failure or end-stage requiring renal replacement in the long term.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description CT scan with iodinated contrast agents CT scan with iodinated contrast agents Patients under 16 years old and must pass a CT scan with iodinated contrast agents. The following data will be collected in the medical record (creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern).
- Primary Outcome Measures
Name Time Method Diuresis change from baseline diuresis at 7 days data gathered in the medical file
Creatinine change from baseline creatinine at 7 days data gathered in the medical file
- Secondary Outcome Measures
Name Time Method Death at 7 days Number of dead
Renal replacement at 7 days Number of patients with no or having an adverse event during the renal replacement.
Readmission at 7 days Number of patients with no or having an adverse event during the readmission.
Hospitalization in intensive care at 7 days Number of patients with no or having an adverse event during the hospitalization in intensive care.
Trial Locations
- Locations (2)
Chu Saint-Etienne
🇫🇷Saint Etienne, France
CHU de Lyon
🇫🇷Lyon, France